Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial
Skyhawk Therapeutics’ RNA-splicing candidate for Huntington’s disease improved patients’ symptoms in an early stage-trial, the company said, as it moves to pivotal development. The therapy, called SKY-0515, led to a 1.59-point improvement on a disease ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Novartis' TREM2 drug fails Phase 2 ALS trial endpoints.news
